South Korea's Eubiologics Invests in Cholera Oral Vaccine Products

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Based on support from the Bill & Melinda Gates Foundation (BMGF) in accordance with the "Ending Cholera 2030" campaign, South Korea's Eubiologics has completed the construction of a production line for cholera oral vaccine drug substance (DS) and is preparing for commercial production.

In addition, Eubiologics is entering the construction planning stage as it has finalized its plan to expand a production line of cholera oral vaccine drug product (DP) to support the campaign.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharma & Biotech Project Database can see detailed reports on the drug substance and drug product projects.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).